Literature DB >> 9829154

Current recommendations for the prophylaxis and treatment of rabies.

D W Dreesen1, C A Hanlon.   

Abstract

Once onset of clinical rabies develops in an individual, death is inevitable. Thus, it is imperative that, for persons exposed or potentially exposed to rabies virus, prophylaxis must be instituted as soon as possible following the exposure. Local wound management is an essential part of postexposure rabies prophylaxis. Exposed persons should receive a recommended series of a tissue culture or cell culture origin vaccine. The number of doses and route of vaccination differ in various regions of the world and are discussed in the text. The administration of a rabies immune globulin is generally recommended in conjunction with the first dose of the rabies vaccine. Nerve tissue origin vaccines, although used extensively in some parts of the world, are not recommended if cell or tissue culture vaccines are available. Decision trees are presented in the text to aid in determining if rabies vaccine is necessary following a known or presumed exposure to the virus, along with a table outlining the various rabies vaccines available in the World. Rabies pre-exposure immunisation is recommended for those individuals at risk of exposure to the virus. Pre-exposure prophylaxis consists of 3 doses of an approved rabies vaccine administered either intramuscularly or intradermally on days 0, 7, and 21 or 28 with periodic booster doses or titre determination depending on the level of risk of potential exposure to the virus.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9829154     DOI: 10.2165/00003495-199856050-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  5 in total

1.  Rabies prevention--United States, 1991. Recommendations of the Immunization Practices Advisory Committee (ACIP).

Authors: 
Journal:  MMWR Recomm Rep       Date:  1991-03-22

2.  Immune response to simulated postexposure rabies booster vaccinations in volunteers who received preexposure vaccinations.

Authors:  C Kositprapa; K Limsuwun; H Wilde; W Jaijaroensup; A Saikasem; P Khawplod; U Kri-aksorn; C Supich
Journal:  Clin Infect Dis       Date:  1997-09       Impact factor: 9.079

Review 3.  A global review of rabies vaccines for human use.

Authors:  D W Dreesen
Journal:  Vaccine       Date:  1997       Impact factor: 3.641

4.  Value of skin testing for predicting reactions to equine rabies immune globulin.

Authors:  T Tantawichien; M Benjavongkulchai; H Wilde; W Jaijaroensup; A Siakasem; S Chareonwai; C Yountong; V Sitprija
Journal:  Clin Infect Dis       Date:  1995-09       Impact factor: 9.079

5.  Human rabies--Texas and New Jersey, 1997.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1998-01-16       Impact factor: 17.586

  5 in total
  3 in total

Review 1.  Rabies: a review of UK management.

Authors:  N McKay; L Wallis
Journal:  Emerg Med J       Date:  2005-05       Impact factor: 2.740

2.  Effective post-exposure treatment of Ebola infection.

Authors:  Heinz Feldmann; Steven M Jones; Kathleen M Daddario-DiCaprio; Joan B Geisbert; Ute Ströher; Allen Grolla; Mike Bray; Elizabeth A Fritz; Lisa Fernando; Friederike Feldmann; Lisa E Hensley; Thomas W Geisbert
Journal:  PLoS Pathog       Date:  2007-01       Impact factor: 6.823

3.  Development in Immunoprophylaxis against Rabies for Animals and Humans.

Authors:  Sukdeb Nandi; Manoj Kumar
Journal:  Avicenna J Med Biotechnol       Date:  2010-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.